Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Lowered to “Sell” at Wall Street Zen

Reviva Pharmaceuticals (NASDAQ:RVPH) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other brokerages have also recently issued reports on RVPH. D. Boral Capital cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Finally, Maxim Group cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Reviva Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $66.67.

Reviva Pharmaceuticals Trading Up 16.8%

Shares of RVPH opened at $0.72 on Friday. Reviva Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $17.98. The stock has a 50 day simple moving average of $0.69 and a 200-day simple moving average of $4.73. The stock has a market cap of $9.37 million, a PE ratio of -0.18 and a beta of 0.56.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). On average, sell-side analysts forecast that Reviva Pharmaceuticals will post -2.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Large investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in Reviva Pharmaceuticals during the 2nd quarter worth approximately $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 3rd quarter worth approximately $37,000. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 1st quarter worth approximately $58,000. State Street Corp grew its position in Reviva Pharmaceuticals by 202.4% during the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after acquiring an additional 256,500 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after acquiring an additional 29,063 shares during the last quarter. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.